Eurocastle Investment Limited
Contact:
Oak Fund Services (Guernsey) Limited
Company Administrator
Attn: Mark Woodall
Tel: +44 1481 723450
Eurocastle to Release Fourth Quarter 2020 Financial Results on 5 March 2021
Guernsey, 3 March, 2021 – Eurocastle Investment Limited ("Eurocastle" or the "Company") today announces that it will release its financial results for the twelve months ended 31 December 2020 on Friday, 5 March 2021 before the market opens.
ABOUT EUROCASTLE
Eurocastle Investment Limited (the "Company" or "Eurocastle") is a publicly traded closed-ended investment company with investments focused on Italian performing and non-performing loans, Italian loan servicing platforms and other real estate related assets in Italy. On 18 November 2019, the Company announced a plan to realise the majority of its assets with the aim of accelerating the return of value to shareholders. The Company does not currently intend to seek new investments from the proceeds of the realisation but will continue to support its existing investments to the extent required in order to optimise returns and distribute cash to shareholders when available (the "Realisation Plan"). For more information regarding Eurocastle Investment Limited and to be added to our email distribution list, please visit www.eurocastleinv.com.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Biotalys NV18.9.2025 07:00:00 CEST | Press release
Biotalys Reports Half-Year 2025 Financial Results and Business Highlights
F. Hoffmann-La Roche Ltd18.9.2025 07:00:00 CEST | Press release
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
Ascom Holding AG18.9.2025 06:30:00 CEST | Press release
Michael Reitermann takes over the operational leadership of the Ascom Group as Delegate of the Board of Directors and interim CEO
Novo Nordisk A/S17.9.2025 23:05:02 CEST | Press release
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Biogen Inc.17.9.2025 22:30:05 CEST | Press release
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom